[1]李赛赛,徐 伟,王煜昊,等.创新药物医保目录准入研究[J].卫生经济研究,2019,(10):40-43.
　LI Sai-sai,XU Wei,WANG Yu-hao,et al.Research on Access to the List of Innovative Medicines[J].Journal Press of Health Economics Research,2019,(10):40-43.
点击复制

创新药物医保目录准入研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2019年10期
页码:
40-43
栏目:
医保天地
出版日期:
2019-09-30

文章信息/Info

Title:
Research on Access to the List of Innovative Medicines
作者:
李赛赛1; 徐 伟1; 王煜昊1; 路娜娜1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
LI Sai-sai; XU Wei; WANG Yu-hao; LU Na-na
School of International Pharmaceutical Business，China Pharmaceutical University，Nanjing Jiangsu 211198，China
关键词:
创新药物; 医保药品目录; 准入周期
Keywords:
innovative medicine; list of insured drugs; access to cycle
分类号:
R195
文献标志码:
A
摘要:
目的：为完善我国创新药物医保目录准入机制提供参考。方法：梳理创新药物纳入医保药品目录的国际现状，从申请主体、准入路径及标准、准入周期等角度，分析影响创新药物医保目录准入的因素。结果：我国大陆地区创新药物的医保准入等待期较长、准入标准及周期不明确。结论：建议逐步放开并规范创新药物医保准入企业申报制、制定明晰的创新药物医保准入路径和准入标准、制定快速固定的创新药物医保准入周期并落实到位。
Abstract:
Objective To provide reference for improving the access mechanism of innovative medicines covered by medical insurance in China. Methods To sort out the international status quo of innovative drugs in the medical insurance drug list， and analyze influencing factors from the perspectives of application subjects， access routes and standards， and access cycles. Results The waiting period for medical insurance access for innovative drugs in mainland China was long， and the admission criteria and cycle were not clear. Conclusion It is recommended to gradually liberalize and standardize the application system for innovative drug medical insurance access， formulate clear access routes and access standards for innovative drug， and formulate a fast-fixing medical insurance access permit period and put it into place.

参考文献/References:

[1] 段晓托,连桂玉,贾耀珠.我国创新药进入医保目录的障碍与对策[J].中国药房,2017,28(4):455-457.
[2] 徐伟,白婕.我国创新药物国家医保目录准入情况研究[J].中国药房,2016,27(33):4609-4612.
[3] 李洪,张玉丽,谢诗桐,等.我国医疗保险目录准入申报材料递交的思考与建议——以高血压复方制剂为例[J].中国药物经济学,2018,13(7):18-23，42.
[4] 徐伟,马丽,高楠.医保药品目录动态调整机制研究[J].卫生经济研究,2017(11):51-53.

相似文献/References:

[1]徐 伟,马 丽,高 楠.医保药品目录动态调整机制研究[J].卫生经济研究,2017,(11):51.
[2]谭清立,林岱衡.论医保统筹进程中的医保药品目录管理[J].卫生经济研究,2021,38(3):50.
　TAN Qing-li,LIN Dai-heng.Discussion on the Management of Medical Insurance Drug Catalogue in the Process of Social Pooling for Medical Insurance[J].Journal Press of Health Economics Research,2021,38(10):50.
[3]孙志成,王舒琦,刘 昭,等.利益相关者视角下创新药物筹资支付路径研究[J].卫生经济研究,2022,39(3):9.
　SUN Zhi-cheng,WANG Shu-qi,LIU Zhao,et al.Research on the Pathway of Innovative Drug Financing and Payment from the Perspective of Stakeholders[J].Journal Press of Health Economics Research,2022,39(10):9.
[4]张明敏,王国平.2021版国家医保药品目录限定支付情况研究[J].卫生经济研究,2023,40(3):72.
　ZHANG Mingmin,WANG Guoping.Study on the Limited Payment of Medical Insurance Drug List 2021[J].Journal Press of Health Economics Research,2023,40(10):72.
[5]郑王彪,郑 超,孙 强.医保药品目录动态调整的国际经验与启示[J].卫生经济研究,2023,40(12):62.
　ZHENG Wangbiao,ZHENG Chao,SUN Qiang.International Experience and Enlightenment on the Dynamic Adjustment of Medical Insurance Drug Catalog[J].Journal Press of Health Economics Research,2023,40(10):62.

更新日期/Last Update: 2019-09-30